- |||||||||| tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Trial primary completion date, Combination therapy, Metastases: Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Jan 19, 2016 P1/2, N=47, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2015
- |||||||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 19, 2016 P2, N=92, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jul 2015 Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 17, 2016 P1/2, N=24, Recruiting, Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: May 2016 --> May 2018
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 17, 2016 P2, N=120, Recruiting, Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Apr 2016 --> Jul 2016
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Trial initiation date, Surgery: Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining (clinicaltrials.gov) - Dec 30, 2015 P=N/A, N=40, Recruiting, Trial primary completion date: Jan 2017 --> Jan 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2015 --> Nov 2015
- |||||||||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment open, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Dec 29, 2015 P1, N=9, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) - Dec 25, 2015 P1, N=16, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015
- |||||||||| Trial primary completion date, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Dec 23, 2015
P2, N=32, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Jul 2016
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: PRODIGE 18: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Dec 18, 2015 P2, N=132, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Oct 2015
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Dec 15, 2015 P1/2, N=25, Recruiting, Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Sep 2013 --> Sep 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2015 P2, N=375, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2016 Trial primary completion date: Mar 2015 --> Mar 2016
|